The most common atezolizumab AESIs included hyperthyroidism (13%; based on laboratory abnormalities detected through frequent testing of thyroid hormones), hypothyroidism (11%), increased ALT and aspartate aminotransferase (both 8%), increased lipase (8%), hepatocellular injury, rash, maculopapular rash and squamous cell carcinoma (5% each). This evidence concerns the gene GPT and hypothyroidism.